

ANNEXES

Annex 1:

First author publications pertaining to written drug information

Facsimile 1 _____ A5

Facsimile 2 _____ A11

Facsimile 3 _____ A21

Facsimile 4 _____ A25

Facsimile 5 _____ A39

Facsimile 6 _____ A53

Annex 2:

Full publication list of the author _____ A61

ANNEX 1
First author publications
pertaining to written drug information

Facsimile 1: _____ **A5**

Vander Stichele RH, Van Haecht CH, Braem MD, Bogaert MG.
Attitude of the public towards technical package inserts for
medication information in Belgium.
DICP (Ann Pharmacother) 1991;25:1002-1006.

Facsimile 2: _____ **A11**

Vander Stichele RH, De Potter B, Vyncke P, Bogaert MG.
Attitude of physicians toward patient package inserts for
medication in Belgium.
Pat Educ Counsel 1996;28: 5-13.

Facsimile 3: _____ **A21**

Vander Stichele RH, Mestdagh J, Van Haecht CHM, De Potter B, Bogaert
MG.
Medication utilization and patient information in homes for the aged.
Eur J Clin Pharmacol 1992;43:319-321.

Facsimile 4: _____ **A25**

Vander Stichele R. Promises of a measurement breakthrough.
In: Métry JM, Meyer UA (Eds). Drug regimen compliance.
Issues in clinical trials and patient management.
John Wiley & Sons, New York, 1999: pp 71-83.

Facsimile 5: _____ **A39**

Vander Stichele RH, Thomson M, Verkoelen K, Droussin AM.
Measuring patient compliance with electronic monitoring:
lisinopril versus atenolol in essential hypertension.
Post Market Surveill (Pharmacoepidemiol Drug Saf) 1992;6:77-90.

Facsimile 6: _____ **A53**

Vander Stichele RH, Van Dierendonck A, G. De Vooght, Reynvoet B,
Lammertyn J.
Impact of benefit messages in patient package inserts on
subjective drug perception.
Drug Inform J 2002;26:201-208.

